Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Cefuroxime nebulised		Hospital only
Ceritinib	TA500 - Ceritinib for untreated ALK-positive non-small-cell lung cancer TA395 - Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer	For hospital use only
Certolizumab injection	TA186 - Rheumatoid arthritis - Certolizumab pegol TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA574 - Certolizumab pegol for treating moderate to severe plaque psoriasis	Hospital use only
Cetaphen 10% topical ointment
Cetrorelix injection
Cetuximab infusion	TA172 - Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck TA145 - Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck TA439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer TA118 - Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer TA473 - Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck	National CDF list. For hospital use only.
Chloral hydrate solution
Chlorambucil tablets	TA344 - Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia TA343 - Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Chlorhexidine bladder wash
Chlorhexidine gluconate 1% dental gel

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.